Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial

Purpose: Late gastrointestinal (GI) toxicity after radiotherapy for prostate cancer may have significant impact on the cancer survivor's quality of life. To date, little is known about local dose-effects after modern radiotherapy including hypofractionation. In the current study we related the local spatial distribution of radiation dose in the rectum to late patient-reported gastrointestinal (GI) toxicities for conventionally fractionated (CF) and hypofractionated (HF) modern radiotherapy in the randomized HYPRO trial.Material and Methods: Patients treated to 78 Gy in 2 Gy fractions (n = 298) or 64.6 Gy in 3.4 Gy fractions (n = 295) with available late toxicity questionnaires (n ≥ 2 within 1–5 years post-treatment) and available 3D planning data were eligible for this study. The majority received intensity modulated radiotherapy (IMRT). We calculated two types of dose surface maps: (1) the total delineated rectum with its central axis scaled to unity, and (2) the delineated rectum with a length of 7 cm along its central axis aligned on the prostate's half-height point (prostate-half). For each patient-reported GI symptom, dose difference maps were constructed by subtracting average co-registered EQD2 (equivalent dose in 2 Gy) dose maps of patients with and without the symptom of interest, separately for HF and CF. P-values were derived from permutation tests. We evaluated patient-reported moderate to severe GI symptoms.Results: Observed incidences of rectal bleeding...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Authors: Chang C, Wu H, Lu Q Abstract Food allergy is a global health problem, particularly in developed countries. It is mainly mediated by Th2 cell and IgE produced by B cells. While the pathogenesis of IgE-mediated food allergy is quite straightforward, the factors that lead to the development of food allergies at any age in children and adults are unclear. Recent studies have revealed that genetics, epigenetics, and environmental exposures contribute to the development of atopy. In this chapter, we discuss the interplay between these three key elements, reveal how epigenetic modifications may mediate genetic su...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Ceribelli A, Selmi C Abstract Genomic predisposition fails to fully explain the onset of complex diseases, which is well illustrated by the largely incomplete concordance among monozygotic twins. Epigenetic mechanisms, including DNA methylation, chromatin remodeling, and non-coding RNA, are the link between environmental stimuli and disease onset on a permissive genetic background in autoimmune and chronic inflammatory diseases. Autoimmune diseases now include almost 100 conditions and are estimated to cumulatively affect up to 5% of the world population with a healthcare expenditure superior to cancer wor...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Zhang L, Lu Q, Chang C Abstract Epigenetic mechanisms, which include DNA methylation, histone modification, and microRNA (miRNA), can produce heritable phenotypic changes without a change in DNA sequence. Disruption of gene expression patterns which are governed by epigenetics can result in autoimmune diseases, cancers, and various other maladies. Mechanisms of epigenetics include DNA methylation (and demethylation), histone modifications, and non-coding RNAs such as microRNAs. Compared to numerous studies that have focused on the field of genetics, research on epigenetics is fairly recent. In contrast to ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
OBJECTIVE: The purpose of this study is to summarize the evidence for the association between exposure to a motor vehicle collision (MVC) and future low back pain (LBP). LITERATURE SURVEY: Persistent low back pain (LBP) is a relatively common complaint...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
CONCLUSION: Radiological imaging is essential for the management of patients affected by lung cancer. PMID: 32445458 [PubMed - as supplied by publisher]
Source: Current Radiopharmaceuticals - Category: Radiology Tags: Curr Radiopharm Source Type: research
Condition:   Post-operative Pain Control Intervention:   Drug: acetaminophen/codeine vs acetaminophen/oxycodone Sponsor:   59th Medical Wing Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Non Small Cell Lung Cancer Intervention:   Drug: TQ-B3139 Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   ICC;   Metastatic Cancer Interventions:   Drug: Folfirinox;   Drug: Sintilimab Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Invasive Interventions:   Drug: Pyrotinib;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Nab-paclitaxel;   Drug: EC chemotherapy;   Drug: Physician's choice;   Drug: T-DM1;   Procedure: Surgery Sponsors:   Shanghai Jiao Tong University School of Medicine;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Augmenix said today that the American Medical Association established a Current Procedural Terminology code for its SpaceOar hydrogel and similar devices, with the Centers for Medicare and Medicaid Services setting a payment rate for procedures with the injectable. The Bedford, Mass.-based company said that the AMA established CPT code 55874 for the periprostatic implantation of biodegradable materials, which SpaceOar will be billed under. The code is set to go into effect January 1, 2018. Augmenix also noted that CMS promulgated their 2018 Medicare Hospital Outpatient Prospective Payment System rule to provide an ave...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Oncology Augmenix Inc. Source Type: news
More News: Bleeding | Cancer | Cancer & Oncology | Colorectal Cancer | Gastroenterology | Incontinence | Intensity-Modulated Radiation Therapy | Pain | Prostate Cancer | Study | Toxicology